Keytruda - Articles and news items

FDA approves Merck’s bladder cancer drug

Industry news / 24 May 2017 / Niamh Marriott, Junior Editor

The FDA has approved two new indications for Merck’s Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for bladder cancer…

FDA approves Merck’s head and neck cancer drug

Industry news / 8 August 2016 / Merck

Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon verification and description of clinical benefit in the confirmatory trials…

Merck releases new data for Keytruda at ASCO

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells…

FDA accepts sBLA for Keytruda in head and neck cancer

Industry news / 13 April 2016 / Victoria White, Digital Content Producer

The sBLA is for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+